Passage Bio Inc (NASDAQ:PASG) has a beta value of 1.82 and has seen 2.79 million shares traded in the last trading session. The PASG stock price is -232.5% off its 52-week high price of $1.33 and 35.0% above the 52-week low of $0.26. If we look at the company’s 10-day average daily trading volume, we find that it stood at 23519.0 shares traded. The 3-month trading volume is 319.50K shares.
The consensus among analysts is that Passage Bio Inc (PASG) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 4 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Passage Bio Inc (NASDAQ:PASG) trade information
Sporting 0.86% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the PASG stock price touched $0.4 or saw a rise of 18.57%. Year-to-date, Passage Bio Inc shares have moved -53.11%, while the 5-day performance has seen it change -13.07%. Over the past 30 days, the shares of Passage Bio Inc (NASDAQ:PASG) have changed -16.39%. Short interest in the company has seen 1.78 million shares shorted with days to cover at 5.04.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could jump 93.33% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -1400.0% off the targeted high while a plunge would see the stock gain -1400.0% from current levels.
Passage Bio Inc (PASG) estimates and forecasts
The company’s shares have lost -42.73% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.48% over the past 5 years. Earnings growth for 2025 is a modest 31.21% while over the next 5 years, the company’s earnings are expected to increase by 44.74%.
PASG Dividends
Passage Bio Inc is expected to release its next earnings report on 2025-May-13 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Passage Bio Inc (NASDAQ:PASG)’s Major holders
Insiders own 0.21% of the company shares, while shares held by institutions stand at 57.31% with a share float percentage of 57.43%. Investors are also buoyed by the number of investors in a company, with Passage Bio Inc having a total of 52.0 institutions that hold shares in the company. The top two institutional holders are ORBIMED ADVISORS LLC with over 10.12 million shares worth more than $8.04 million. As of 2024-06-30, ORBIMED ADVISORS LLC held 17.9847% of shares outstanding.
The other major institutional holder is VESTAL POINT CAPITAL, LP, with the holding of over 6.05 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.81 million and represent 10.7504% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Mar 31, 2025 , the former fund manager holds about 2.41% shares in the company for having 1.5 shares of worth $0.6 million while later fund manager owns 493.23 shares of worth $0.2 million as of Mar 31, 2025 , which makes it owner of about 0.79% of company’s outstanding stock.
